HK1186468A1 - 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms 4-[-2-[[5--1-(2-)-1h--3-]]] - Google Patents

4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms 4-[-2-[[5--1-(2-)-1h--3-]]]

Info

Publication number
HK1186468A1
HK1186468A1 HK13113963.1A HK13113963A HK1186468A1 HK 1186468 A1 HK1186468 A1 HK 1186468A1 HK 13113963 A HK13113963 A HK 13113963A HK 1186468 A1 HK1186468 A1 HK 1186468A1
Authority
HK
Hong Kong
Prior art keywords
naphtalenyl
pyrazol
oxy
ethyl
methyl
Prior art date
Application number
HK13113963.1A
Other languages
English (en)
Chinese (zh)
Inventor
Buchholz Jordi Benet
Fernandez Laura Puig
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of HK1186468A1 publication Critical patent/HK1186468A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK13113963.1A 2010-08-09 2013-12-16 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms 4-[-2-[[5--1-(2-)-1h--3-]]] HK1186468A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382225A EP2426111A1 (en) 2010-08-09 2010-08-09 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
PCT/EP2011/063583 WO2012019984A1 (en) 2010-08-09 2011-08-08 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms

Publications (1)

Publication Number Publication Date
HK1186468A1 true HK1186468A1 (en) 2014-03-14

Family

ID=43244877

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13113963.1A HK1186468A1 (en) 2010-08-09 2013-12-16 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms 4-[-2-[[5--1-(2-)-1h--3-]]]

Country Status (19)

Country Link
US (1) US9428462B2 (ja)
EP (2) EP2426111A1 (ja)
JP (1) JP5899214B2 (ja)
KR (1) KR20130095751A (ja)
CN (1) CN103052626B (ja)
AR (1) AR082608A1 (ja)
AU (1) AU2011288550A1 (ja)
BR (1) BR112013002651A2 (ja)
CA (1) CA2807855C (ja)
CO (1) CO6670586A2 (ja)
ES (1) ES2543429T3 (ja)
HK (1) HK1186468A1 (ja)
MA (1) MA34512B1 (ja)
MX (1) MX341711B (ja)
PT (1) PT2603495E (ja)
RU (1) RU2013110313A (ja)
SG (1) SG187745A1 (ja)
TW (1) TW201219387A (ja)
WO (1) WO2012019984A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
US20160310501A1 (en) * 2013-12-17 2016-10-27 Laboratorios Del Dr. Esteve, S.A. Gabapentinoids and sigma receptor ligands combinations
AU2014364647A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Sigma receptor ligands combinations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04364129A (ja) 1990-10-26 1992-12-16 Asahi Chem Ind Co Ltd ６−置換アルコキシキノキサリン誘導体含有医薬組成物およびその製造法
SE508669C2 (sv) 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
PL1781618T3 (pl) * 2004-08-27 2013-03-29 Esteve Labor Dr Inhibitory receptora sigma
EP1634872A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
DK1781618T3 (da) * 2004-08-27 2012-10-29 Esteve Labor Dr Sigma-receptorinhibitorer
EP2191830A4 (en) 2007-09-21 2011-11-23 Shionogi & Co SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP2292236A1 (en) * 2009-08-14 2011-03-09 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention or treatment of pain induced by chemotherapy
EP2361904A1 (en) 2010-02-04 2011-08-31 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof
MY160018A (en) * 2009-11-25 2017-02-15 Esteve Labor Dr 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
EP2335688A1 (en) * 2009-11-25 2011-06-22 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions comprising sigma receptor ligands
EP2426112A1 (en) 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
HUE029738T2 (en) * 2010-02-04 2017-04-28 Esteve Labor Dr 4- [2 - [[5-Methyl-1- (2-naphthalenyl) -1H-pyrazol-3-yl] oxy] ethyl] morpholine hydrochloride polymorphs and solvates
EP2353598A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) * 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) * 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2460519A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain

Also Published As

Publication number Publication date
EP2603495A1 (en) 2013-06-19
US9428462B2 (en) 2016-08-30
JP5899214B2 (ja) 2016-04-06
CA2807855A1 (en) 2012-02-16
EP2603495B1 (en) 2015-05-06
JP2013533298A (ja) 2013-08-22
RU2013110313A (ru) 2014-09-20
PT2603495E (pt) 2015-08-28
KR20130095751A (ko) 2013-08-28
AU2011288550A1 (en) 2013-02-21
US20130150575A1 (en) 2013-06-13
CA2807855C (en) 2018-10-23
WO2012019984A1 (en) 2012-02-16
CN103052626B (zh) 2017-06-06
AR082608A1 (es) 2012-12-19
ES2543429T3 (es) 2015-08-19
MA34512B1 (fr) 2013-09-02
MX341711B (es) 2016-08-31
CN103052626A (zh) 2013-04-17
TW201219387A (en) 2012-05-16
BR112013002651A2 (pt) 2016-05-31
CO6670586A2 (es) 2013-05-15
MX2013001559A (es) 2013-03-07
SG187745A1 (en) 2013-03-28
EP2426111A1 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
HK1186468A1 (en) 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms 4-[-2-[[5--1-(2-)-1h--3-]]]
HK1179477A1 (en) Kinase inhibitors
IL221277A0 (en) 4 - [- 2 - [[5 - methyl- 1 - (2 - naphtalenyl) - 1h - pyrazol - 3 - yl] oxy ] ethyl] morpholine hydrochloride polymorphs and solvates
ZA201203842B (en) Kinase inhibitors
IL211863A0 (en) Reduced size self-delivering rnai compounds
EP2402918A4 (en) DEVICE FOR SORTING AND BINDER PROCESSING OF BANKNOTES
EP2558099A4 (en) Kinase Inhibitors
IL219997A0 (en) 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
EP2501681A4 (en) ACRIDINIUM COMPOUNDS CONTAINING ZWITTERION
IL214293A0 (en) Dihydroquinolinone derivatives
IL214251A0 (en) Isoxazole derivatives
EP2480076A4 (en) IMIDAZOTHIAZOLIC INHIBITORS OF KINASES
HK1201759A1 (en) 4-methylpyrazole formulations 4-
ZA201107435B (en) Pyrazole copmpound
EP2449565A4 (en) Ignition coil
PL2646448T3 (pl) Makrocykliczne inhibitory kinazy
HK1178522A1 (en) Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents
IL220307A (en) Secondary history of 8-hydroxyquinoline-7-carboxamide
GB0914726D0 (en) Kinase inhibitors
AU4436P (en) Selexion Valerianella locusta
GB2470588B (en) Drawing aid
AU2009901386A0 (en) Coil arrangement
AU2009901941A0 (en) Adjustable insert
AU2009905324A0 (en) Golf Improvement Aid
GB0916245D0 (en) Compensating for hysteresis

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190814